Clinical OMICs - Volume 3, Issue 9 - 15

For instance, tamoxifen, a medication prescribed for the treatment of breast cancer, often has a poor patient response due to lack of receptor coverage. Research conducted on patients taking tamoxifen used LC-MS-based assays to monitor the drug's distribution and found that measuring multiple relevant analytes in tandem is useful in providing a wider picture with regards to therapeutic uptake and treatment efficacy. This study demonstrates the power of LC-MS for patient profiling and highlights its ability to help clinicians make more informed decisions based on how likely the patient is to respond to treatment6. The Future of Medicine Clinicians will increasingly require more sensitive technologies for targeted and untargeted diagnostic testing. As such, clinical researchers are looking to utilize the most sensitive triple quadrupole mass spectrometry available for targeted testing, as well as investigating the potential to leverage the strengths offered by orbitrap mass analyzer technology, which show promise to enable effective detection of multiple, predictive biomarkers. This data could be used to infer the presence and severity of disease, the likelihood of therapeutic success and the pharmacokinetics of a drug once administered. This method of biomarker analysis, while still in a research phase, may be used long-term to monitor the real-time response of patients to treatments in a non-invasive way. For example, imagine a future where www.clinicalomics.com patients suffering from melanoma might not require multiple painful bone marrow biopsies for the monitoring of residual disease, but could instead be rapidly and easily monitored using a blood test, minimizing patient discomfort. Further, LCMS could play a key factor in immunotherapy approaches to identify new targets for cancer therapy to enable more robust antitumor responses7. In summary, LC-MS offers clinical researchers, healthcare providers, and patients the promise of more effective, personalized therapeutic regimens based upon individual data relating to therapeutic response and/ or particular indicators of disease stage/severity. As a technique offering higher analytical resolution, the universal adoption of LC-MS systems can support the drive for medical advances across a broad range of clinical research and diagnostic applications, helping to improve the way we understand and treat disease. REFERENCES 1. Sallustio BC (2010) LC-MS/MS for immunosuppressant therapeutic drug monitoring, Bioanalysis. 2(6):1141-53. doi: 10.4155/bio.10.58. 2. Tate J, and Ward G (2004) Interferences in Immunoassay, Clin Biochem Rev, 25 (2): 105 - 120 3. Bhavin, P (2016) Quantitative Analysis of IGF1R/AKT/mTOR Pathway using Multiplex-Immunoprecipitation and Targeted Mass Spectrometry. Retrieved from: http://tools.thermofisher.com/content/sfs/brochures/ PO-64813-AACR-2016-bhavin-p-aacr-poster-EN.pdf 4. Fang et al (2010) Scaling discovery proteomics to large lung cancer cohorts using data independent acquisition. Retrieved from: http:// apps.thermoscientific.com/media/cmd/flipbooks/PO64814_041316_ AACR2016_Peterman_Poster_Final.pdf 5. Kushnir, M. M., Rockwood, A. L. and Bergquist, J. (2010), Liquid chromatography-tandem mass spectrometry applications in endocrinology. Mass Spectrom. Rev., 29: 480-502. doi:10.1002/mas.20264 6. Clarke N (2015) Phenotypings for Pharmacogenomics and Precision Medicine. Retrieved From: https://www.msacl.org/index. php?header=Learning_Center&tab=Video_Management&subtab=Video_ Request&id=11&conference =2015_US&type=plenary 7. Blasutig, I. and Siu, L. (2016), New Immunotherapies: The Beginning of the End of Cancer. Presentation. Check out our new website: www.clinicalomics.com Robust, dynamic and essential! September 2016 Clinical OMICs 15 http://tools.thermofisher.com/content/sfs/brochures/PO-64813-AACR-2016-bhavin-p-accr-poster-EN.pdf http://tools.thermofisher.com/content/sfs/brochures/PO-64813-AACR-2016-bhavin-p-accr-poster-EN.pdf http://apps.thermoscientific.com/media/cmd/flipbooks/PO64814_041316_AACR2016_Peterman_Poster_Final.pdf http://apps.thermoscientific.com/media/cmd/flipbooks/PO64814_041316_AACR2016_Peterman_Poster_Final.pdf http://apps.thermoscientific.com/media/cmd/flipbooks/PO64814_041316_AACR2016_Peterman_Poster_Final.pdf https://www.msacl.org/index.php?header=Learning_Center&tab=Video_Management&subtab=Video_Request&id=11&conference https://www.msacl.org/index.php?header=Learning_Center&tab=Video_Management&subtab=Video_Request&id=11&conference https://www.msacl.org/index.php?header=Learning_Center&tab=Video_Management&subtab=Video_Request&id=11&conference http://www.clinicalomics.com http://www.clinicalomics.com

Table of Contents for the Digital Edition of Clinical OMICs - Volume 3, Issue 9